Mirae Asset Global Investments Co. Ltd. Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Mirae Asset Global Investments Co. Ltd. increased its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 3.2% in the 4th quarter, HoldingsChannel reports. The fund owned 12,898 shares of the company’s stock after purchasing an additional 404 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Keros Therapeutics were worth $513,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KROS. China Universal Asset Management Co. Ltd. lifted its stake in shares of Keros Therapeutics by 356.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock valued at $138,000 after purchasing an additional 2,702 shares during the last quarter. Arizona State Retirement System purchased a new stake in Keros Therapeutics in the 4th quarter valued at about $231,000. TD Asset Management Inc lifted its position in Keros Therapeutics by 100.0% in the third quarter. TD Asset Management Inc now owns 36,200 shares of the company’s stock valued at $1,154,000 after buying an additional 18,100 shares during the last quarter. Swiss National Bank boosted its stake in Keros Therapeutics by 4.8% during the third quarter. Swiss National Bank now owns 45,600 shares of the company’s stock worth $1,454,000 after buying an additional 2,100 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Keros Therapeutics by 466.7% during the third quarter. SG Americas Securities LLC now owns 47,183 shares of the company’s stock valued at $1,504,000 after acquiring an additional 38,857 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Trading Down 3.6 %

NASDAQ:KROS opened at $54.19 on Friday. Keros Therapeutics, Inc. has a 12-month low of $27.02 and a 12-month high of $73.00. The firm has a market cap of $1.95 billion, a PE ratio of -10.42 and a beta of 1.26. The stock has a fifty day moving average price of $63.61 and a 200 day moving average price of $47.66.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Friday, March 1st. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $0.14 million during the quarter. During the same quarter in the prior year, the company earned ($1.09) earnings per share. Equities analysts forecast that Keros Therapeutics, Inc. will post -5.11 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $105.00 price objective on shares of Keros Therapeutics in a research report on Wednesday, March 27th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Friday, March 1st. Truist Financial reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Wednesday, March 13th. William Blair restated an “outperform” rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Finally, Wedbush reiterated an “outperform” rating and set a $86.00 price target on shares of Keros Therapeutics in a research note on Thursday, February 29th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Keros Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $86.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.